Skip to main content
Premium Trial:

Request an Annual Quote

Nucleix Raises Additional $22M

This article has been updated to correct information about Nucleix's partnership with the MD Anderson Cancer Center.

NEW YORK — Israeli cancer diagnostics developer Nucleix said on Wednesday that it raised $22 million in December, extending a financing round closed earlier last year.

The additional investment was led by Sands Capital and follows a $55 million oversubscribed financing round Nucleix closed in April, bringing the total amount raised by the firm in 2021 to $77 million.

Nucleix is developing liquid biopsy tests for early-stage and recurring cancer diagnosis that use PCR and next-generation sequencing technologies to detect tissue-specific methylation patterns on circulating tumor DNA that can be analyzed using proprietary software.

The company currently markets a bladder cancer recurrence test — called Bladder EpiCheck — in Europe and is awaiting 510(k) clearance from the US Food and Drug Administration for the assay. It has also developed a lung cancer early detection test, called Lung EpiCheck, and is working on another lung cancer test that uses the EpiCheck platform in partnership with the MD Anderson Cancer Center.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.